(2-amino-5-propargyloxy-phenyl)-(4-isopropylphenyl)methanone | 478964-94-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (2-amino-5-propargyloxy-phenyl)-(4-isopropylphenyl)methanone
• 英文别名: (2-amino-5-propargyloxy-phenyl)-(4-isopropyl-phenyl)-methanone；(2-Amino-5-(prop-2-yn-1-yloxy)phenyl)(4-isopropylphenyl)methanone；(2-amino-5-prop-2-ynoxyphenyl)-(4-propan-2-ylphenyl)methanone
• CAS: 478964-94-2
• 化学式: C₁₉H₁₉NO₂
• 分子量: 293.365
• InChiKey: HBYLMGWRSGFFMJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  22
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  52.3
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 储存条件：
  2-8℃

反应信息

• 作为反应物：
  描述：

  (2-amino-5-propargyloxy-phenyl)-(4-isopropylphenyl)methanone 在 甲基磺酰氯 、 N,N-二异丙基乙胺 作用下， 以 1,4-二氧六环 为溶剂， 反应 0.08h， 生成 (4-isopropyl-phenyl)-(2-{[2-(2-methoxy-ethoxy)-pyridin-3-ylmethyl]-amino}-5-prop-2-ynyloxy-phenyl)-methanone
  参考文献：
  名称：

  [EN] DERIVATIVES OF ARYL-QUINAZOLINE/ARYL-2AMINO-PHENYL METHANONE WHICH PROMOTE THE RELEASE OF PARATHYROID HORMONE
  [FR] DERIVES D'ARYL-QUINAZOLINE/ARYL-2AMINO-PHENYL METHANONE

  摘要：

  公开号：

  WO2004056365A3
• 作为产物：
  描述：

  (4-异丙基苯基)(2-硝基-5-(2-丙炔氧基)苯基)甲酮 在 铁粉 、 溶剂黄146 作用下， 反应 16.0h， 以77%的产率得到(2-amino-5-propargyloxy-phenyl)-(4-isopropylphenyl)methanone
  参考文献：
  名称：

  1-Alkyl-4-phenyl-6-alkoxy-1H-quinazolin-2-ones: A Novel Series of Potent Calcium-Sensing Receptor Antagonists

  摘要：

  Parathyroid hormone (PTH) is an effective bone anabolic agent. However, only when administered by daily sc injections exposure of short duration is achieved, a prerequisite for an anabolic response. Instead of applying exogenous PTH, mobilization of endogenous stores of the hormone can be envisaged. The secretion of PTH stored in the parathyroid glands is mediated by a calcium Sensing receptor (CaSR) a GPCR localized at the cell surface. Antagonists of CaSR (calcilytics) mimic a state of hypocalcaemia and stimulate PTH release to the bloodstream. Screening of the internal compound collection for inhibition of CaSR signaling function afforded 2a. In vitro potency Could be improved > 1000 fold by optimization of its chemical structure. The binding mode of our compounds was predicted based oil molecular modeling and confirmed by testing with Mutated receptors. While the Compounds readily induced PTH release after iv application a special formulation was needed for oral activity. The required profile was achieved by using microemulsions. Excellent PK/PD correlation was found in rats and dogs. High levels of PTH were reached in plasma within Minutes which reverted to baseline in about 1-2 h in both species.

  DOI：

  10.1021/jm901811v

文献信息

• Quinazoline derivatives
  申请人：——

  公开号：US20040180912A1

  公开（公告）日：2004-09-16

  Use of compound of formula (I), wherein, is, or, and wherein the symbols are as defined, or a pharmaceutically-acceptable and-cleavable ester, or acid addition salt thereof, for the preparation of a medicament for promoting the release of parathyroid hormone, e.g. for preventing or treating bone conditions which are associated with increased calcium depletion or resorption or in which stimulation of bone formation and calcium fixation in the bone is desirable. 1

  使用公式（I）的化合物，其中，是，或，其中符号的定义如上所述，或其药学上可接受的可水解酯或酸盐，用于制备促进甲状旁腺激素释放的药物，例如用于预防或治疗与增加的钙耗竭或吸收有关的骨病或需要刺激骨形成和钙固定于骨中的情况。
• Aryl-quinazoline/aryl-2amino-phenyl methanone derivatives
  申请人：Altmann Eva

  公开号：US20060079685A1

  公开（公告）日：2006-04-13

  A compound of formula (I): wherein R1, R2, R3 and Y are as defined herein, or a pharmaceutically-acceptable and -cleavable ester, or acid addition salt thereof, useful for promoting the release of parathyroid hormone, e.g. for preventing or treating bone conditions which are associated with increased calcium depletion or resorption or in which stimulation of bone formation and calcium fixation in the bone is desirable.

  化合物的化学式为(I): 其中R1，R2，R3和Y的定义如下，或其药学上可接受和可水解酯或酸盐，用于促进甲状旁腺激素的释放，例如预防或治疗与钙流失或吸收增加或骨形成和钙固定在骨中有关的骨病情况。
• Benzoquinazoline derivatives
  申请人：Widler Leo

  公开号：US20100099670A1

  公开（公告）日：2010-04-22

  A compound of formula (I) or a pharmaceutically acceptable salt or prodrug ester thereof: wherein R is as defined in the specification.

  化合物式(I)或其药学上可接受的盐或前药酯： 其中R的定义在说明书中。
• BENZOQUINAZOLINE DERIVATIVES
  申请人：Ammon Sandra

  公开号：US20100166765A1

  公开（公告）日：2010-07-01

  A compound of formula (I) or a pharmaceutically acceptable salt or prodrug ester thereof, wherein the groups R2, R3, R4, Q, X and Y are as defined in the specification, is useful in the treatment of bone conditions related to increased calcium depletion or resorption.

  式(I)的化合物或其药学上可接受的盐或前药酯，其中基团R2、R3、R4、Q、X和Y的定义在说明书中，可用于治疗与钙流失或吸收增加有关的骨疾病。
• Quinazoline derivatives which promote the release of parathyroid hormone
  申请人：Beerli René

  公开号：US08476286B2

  公开（公告）日：2013-07-02

  Use of compound of formula (I), wherein, is, or, and wherein the symbols are as defined, or a pharmaceutically-acceptable and -cleavable ester, or acid addition salt thereof, for the preparation of a medicament for promoting the release of parathyroid hormone, e.g. for preventing or treating bone conditions which are associated with increased calcium depletion or resorption or in which stimulation of bone formation and calcium fixation in the bone is desirable.

  使用公式（I）的化合物，其中，是，或，其中符号的定义如下，或其药学上可接受和可水解的酯，或酸加成盐，用于制备促进甲状旁腺激素释放的药物，例如用于预防或治疗与增加的钙耗竭或吸收有关的骨病或骨形成和钙固定在骨中受到欢迎的情况。